On this page
What each program costs in Kentucky
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the Kentucky Employees' Health Plan (KEHP) cover GLP-1s for weight loss?
Kentucky's 2026 LivingWell PPO prescription plan lists weight-management GLP-1s as their own tier, paid at 25% after the deductible in network and 50% after the deductible out of network.
Getting a GLP-1 online in Kentucky
The Kentucky Board of Pharmacy's 2025 guidance says pharmacies generally may not compound semaglutide or tirzepatide, since both are commercially available, unless a prescriber documents a change that makes a significant difference for an individual patient.
Kentucky Board of Pharmacy
The Board's 2025 GLP-1 compounding guidance states the general rule.
“In general, compounding pharmacies may not compound semaglutide or tirzepatide, a commercially available drug product.”
https://pharmacy.ky.gov/professionals/Documents/GLP-1%20Compounding%20Guidance%202025.pdf · read Oct 29, 2026
Kentucky Board of Pharmacy
It describes the narrow exception for a change made for an individual patient.
“Also, the federal FD&C Act states that a compounded drug product is not “essentially a copy” of a commercially available drug product if a change is made for an identified individual patient and the prescribing practitioner has determined that the change will produce a significant difference for that patient.”
https://pharmacy.ky.gov/professionals/Documents/GLP-1%20Compounding%20Guidance%202025.pdf · read Oct 29, 2026
Kentucky Board of Pharmacy
A November 14, 2025 compliance alert reminds pharmacies to buy compounded GLP-1s only from outsourcing facilities legally allowed to make them.
“As stated in the Board’s Opinion and Declaratory Order dated May 22, 2024, pharmacies are expected to procure compounded products only from outsourcing facilities that are legally authorized to compound the product and only dispense such products if the pharmacist is legally authorized to do so in Kentucky.”
https://pharmacy.ky.gov/Documents/Compound%20Compliance%20Alert%20GLP1_GIP%2011.14.2025%281%29.pdf · read Oct 29, 2026
Does Kentucky Medicaid cover GLP-1s for weight loss?
Not covered for weight loss
Kentucky Medicaid's Wegovy criteria cover heart risk reduction or a liver condition and its Zepbound criteria require sleep apnea, so it does not cover them for weight loss alone. Read from state documents Nov 6, 2026.
What Kentucky Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. Kentucky Department for Medicaid Services, through its pharmacy benefit vendor MedImpact.
WegovyNo
Prior authorization for heart risk reduction with existing cardiovascular disease and BMI of 27 or more, or for MASH with liver fibrosis.
“For Major Adverse Cardiovascular Events (MACE) risk reduction:”
MedImpact for Kentucky Department for Medicaid Services · Effective Jan 3, 2026 · read Nov 6, 2026
“For Metabolic Dysfunction-Associated Steatohepatitis (MASH):”
MedImpact for Kentucky Department for Medicaid Services · Effective Jan 3, 2026 · read Nov 6, 2026
ZepboundNo
Prior authorization for moderate to severe sleep apnea in adults with BMI of 30 or more, after a breathing device trial unless not tolerated or contraindicated.
“Diagnosis of moderate to severe obstructive sleep apnea (OSA); AND”
MedImpact for Kentucky Department for Medicaid Services · Effective Jul 1, 2025 · read Nov 6, 2026
OzempicNo
Prior authorization for type 2 diabetes. The GLP-1 class criteria exclude drugs used for weight loss.
“Drugs used for anorexia, weight loss, or weight gain are excluded from coverage.”
MedImpact for Kentucky Department for Medicaid Services · Effective Oct 1, 2026 · read Nov 6, 2026
“Mounjaro AE, CC, QL Ozempic pen AE, CC, QL”
MedImpact for Kentucky Department for Medicaid Services · Effective Oct 1, 2026 · read Nov 6, 2026
MounjaroNo
Prior authorization for type 2 diabetes. The GLP-1 class criteria exclude drugs used for weight loss.
“Drugs used for anorexia, weight loss, or weight gain are excluded from coverage.”
MedImpact for Kentucky Department for Medicaid Services · Effective Oct 1, 2026 · read Nov 6, 2026
“Diagnosis of Type II Diabetes Mellitus (T2DM) confirmed with clinical documentation”
MedImpact for Kentucky Department for Medicaid Services · Effective Oct 1, 2026 · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Kentucky Department for Medicaid Services, through its pharmacy benefit vendor MedImpact documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
3,257 prescriptions
Ozempic and Mounjaro, 2025
240,355 prescriptions
Neighbours covering weight loss
3 of 7
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Kentucky Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Kentucky Medicaid as "not covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Kentucky Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Kentucky Medicaid pay for?
274,170 GLP-1 prescriptions in 2025, 11th of the 50 states and DC, with $238.0 million reimbursed before rebates.
Prescriptions, 2025
274,170
11th of 51
Medicaid paid
$238.0M
12th of 51, before rebates
Per prescription
$868
$1,051 nationally
Weight-loss brands
1.2%
37th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Kentucky is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 1.2% of Kentucky Medicaid's GLP-1 prescriptions in 2025 (3,257). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Ozempic was Kentucky Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Ozempic | 176,529 | 64% | $151.5 million | $858 |
| Mounjaro | 63,826 | 23% | $58.3 million | $913 |
| Trulicity | 26,450 | 9.6% | $22.1 million | $836 |
| Rybelsus | 2,524 | 0.9% | $2.1 million | $821 |
| Zepboundapproved for weight management | 2,432 | 0.9% | $2.4 million | $977 |
| Victoza | 1,311 | 0.5% | $615,912 | $470 |
| Wegovyapproved for weight management | 825 | 0.3% | $953,697 | $1,156 |
| Liraglutide (generic) | 148 | 0.1% | $50,046 | $338 |
| Bydureon | 109 | 0.0% | $74,150 | $680 |
| Byetta | 16 | 0.0% | $9,908 | $619 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
On Medicare in Kentucky?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
Kentucky and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
3 of the 7 states next to Kentucky cover GLP-1s for weight loss through Medicaid: Missouri, Tennessee and Virginia. None has a lower cash floor than Kentucky's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Kentucky | Not covered | 19 | $39/mo |
| Illinois | Not covered | 19 | $39/moWellmedr |
| Indiana | Not covered | 19 | $39/moWellmedr |
| Missouri | Zepbound only | 18 | $39/moWellmedr |
| Ohio | Not covered in part | 19 | $39/moWellmedr |
| Tennessee | Covered | 18 | $39/moWellmedr |
| Virginia | Covered | 19 | $39/moWellmedr |
| West Virginia | Not covered | 18 | $39/moWellmedr |






















